SCHEMBL4079803

SCHEMBL4079803

CC(C)(C)c1cccc(OC(N)=O)c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.44
ATM Q13315 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
GAA P10253 2/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
CA2 P00918 1/20 0.41
BCHE P06276 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
NAMPT P43490 1/20 0.38
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
TSHR P16473 1/20 0.35
ALOX15 P16050 1/20 0.35
ELANE P08246 1/20 0.35
ALOX5 P09917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11466585 0.85 TDP1 (0.58) TDP1ATMMEN1KMT2AALDH1A1
SCHEMBL28561795 0.83 TDP1 (0.42) TDP1ATMMEN1KMT2AALDH1A1
SCHEMBL31039481 0.80 KDM4E (0.40) TDP1ATMMEN1KMT2AALDH1A1
SCHEMBL27635850 0.79 MEN1 (0.45) TDP1ATMMEN1KMT2AALDH1A1
SCHEMBL2481471 0.77 KMT2A (0.40) TDP1ATMMEN1KMT2AALDH1A1
SCHEMBL28823408 0.76 MEN1 (0.45) MEN1KMT2AALDH1A1KDM4ECA2
SCHEMBL28953567 0.76 CA12 (0.48) TDP1MEN1KMT2AALDH1A1KDM4E
SCHEMBL15422590 0.74 NR1H4 (0.42) TDP1ATMMEN1KMT2AALDH1A1
SCHEMBL28392012 0.73 CA1 (0.47) MEN1KMT2AALDH1A1GAACA2
SCHEMBL138254 0.73 CA2 (0.55) TDP1ALDH1A1KDM4ECA2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111848598-A Heterocyclic ring-containing compound, application thereof and composition containing heterocyclic ring-containing compound 健艾仕生物医药有限公司 2020-10-30 CN disclosed
US-9512143-B2 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. (US) 2016-12-06 US disclosed
US-20150158884-A1 HISTONE DEACETYLASE INHIBITORS BIOMARIN PHARM INC (US) 2015-06-11 US disclosed
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES 4SC AG (DE) 2011-03-17 US disclosed
EP-2060565-A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases 4SC AG (DE) 2009-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065734-A1 NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES HDAC1, HDAC11, MAP2K2 TDP1 1844/4885ATM 468/4885MEN1 2479/4885
US-20150158884-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC2, HDAC3 TDP1 1880/4885ATM 2488/4885MEN1 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.